October 21, 2022 02:45 PM EDT
Pharma
Law

Will feds re­clas­si­fy 'mag­ic mush­room' ther­a­pies? Seat­tle doc­tor ramps up court bat­tle

Nicole DeFeudis

Editor

As psy­che­del­ic ther­a­pies make their way through the clin­ic, one Seat­tle doc­tor is tak­ing his fight to change psilo­cy­bin’s sta­tus as a Sched­ule I sub­stance …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Watch Post-Hoc Live: Trump's 'most fa­vored na­tion' plan to cut drug prices

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

It's been three months with­out a biotech IPO

A service from the Financial Times